Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Zhuhai Rundu Pharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Zhuhai Rundu Pharmaceutical's earnings have been declining at an average annual rate of -6.1%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 0.07% per year. Zhuhai Rundu Pharmaceutical's return on equity is 3.1%, and it has net margins of 2.9%.
Anahtar bilgiler
-6.1%
Kazanç büyüme oranı
-6.0%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 0.07% |
| Özkaynak getirisi | 3.1% |
| Net Marj | 2.9% |
| Sonraki Kazanç Güncellemesi | 29 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Zhuhai Rundu Pharmaceutical's (SZSE:002923) Dividend Is Being Reduced To CN¥0.20
May 29
There May Be Reason For Hope In Zhuhai Rundu Pharmaceutical's (SZSE:002923) Disappointing Earnings
May 05There's Reason For Concern Over Zhuhai Rundu Pharmaceutical Co., Ltd.'s (SZSE:002923) Massive 32% Price Jump
Mar 05Gelir ve Gider Dağılımı
Zhuhai Rundu Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 1,234 | 35 | 359 | 144 |
| 31 Mar 24 | 1,239 | 56 | 381 | 132 |
| 31 Dec 23 | 1,292 | 67 | 392 | 127 |
| 30 Sep 23 | 1,326 | 119 | 415 | 108 |
| 30 Jun 23 | 1,369 | 150 | 420 | 94 |
| 31 Mar 23 | 1,409 | 158 | 439 | 91 |
| 01 Jan 23 | 1,372 | 155 | 462 | 92 |
| 30 Sep 22 | 1,319 | 153 | 471 | 86 |
| 30 Jun 22 | 1,274 | 150 | 476 | 90 |
| 31 Mar 22 | 1,189 | 143 | 462 | 87 |
| 01 Jan 22 | 1,190 | 140 | 476 | 84 |
| 30 Sep 21 | 1,157 | 114 | 475 | 83 |
| 30 Jun 21 | 1,172 | 124 | 475 | 81 |
| 31 Mar 21 | 1,259 | 139 | 522 | 88 |
| 31 Dec 20 | 1,253 | 136 | 528 | 94 |
| 30 Sep 20 | 1,299 | 131 | 612 | 105 |
| 30 Jun 20 | 1,324 | 130 | 666 | 105 |
| 31 Mar 20 | 1,337 | 122 | 712 | 104 |
| 31 Dec 19 | 1,360 | 119 | 745 | 115 |
| 30 Sep 19 | 1,312 | 125 | 737 | 105 |
| 30 Jun 19 | 1,258 | 120 | 717 | 101 |
| 31 Mar 19 | 1,162 | 116 | 664 | 90 |
| 01 Jan 19 | 1,044 | 107 | 608 | 66 |
| 30 Sep 18 | 970 | 103 | 514 | 87 |
| 30 Jun 18 | 884 | 97 | 439 | 67 |
| 31 Mar 18 | 816 | 92 | 382 | 55 |
| 31 Dec 17 | 779 | 91 | 347 | 45 |
| 31 Dec 16 | 652 | 87 | 319 | 0 |
| 31 Dec 15 | 578 | 71 | 294 | 0 |
| 31 Dec 14 | 524 | 60 | 272 | 0 |
| 31 Dec 13 | 434 | 59 | 217 | 0 |
Kaliteli Kazançlar: 002923 has a large one-off gain of CN¥33.7M impacting its last 12 months of financial results to 30th June, 2024.
Büyüyen Kar Marjı: 002923's current net profit margins (2.9%) are lower than last year (10.9%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 002923's earnings have declined by 6.1% per year over the past 5 years.
Büyüme Hızlandırma: 002923's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: 002923 had negative earnings growth (-76.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.6%).
Özkaynak Getirisi
Yüksek ROE: 002923's Return on Equity (3.1%) is considered low.